procisedx.comCrawled Nov 14, 2026
Therapeutic Drug Monitoring (TDM) of antitumor necrosis factor (TNF) drugs like Adalimumab has grown as doctors refine IBD treatment. TDM checks trough levels before dosing to maintain proper medication levels, though prior testing methods took days or weeks for results.
C-Reactive Protein (CRP) is a liver-produced marker of inflammation that rises during acute inflammation or infection, aiding in monitoring inflammatory bowel disease (IBD).
Fecal calprotectin helps distinguish irritable bowel syndrome (IBS) from inflammatory bowel diseases (IBD) as a stable biomarker unaffected by medication or dietary supplements. It provides diagnostic clarity and tracks ongoing treatment progress.
Over the past two decades great improvements in therapy of chronic inflammatory diseases have been made. The rise of TNF biologics like infliximab has been a great step forward to ameliorating disease course and keep inflammations at remission levels for prolonged periods of time. Therapeutic Drug Monitoring (TDM) of biotherapies is a well recognized tool allowing a better usage of biotherapies by making evidence-based treatment decisions.
The page offers a recording of an event upon registration.
SAN DIEGO, July 13, 2021 /PRNewswire/ -- ProciseDx Inc. announces a $13 million convertible note financing to support international commercialization of the ProciseDx platform and US regulatory approval. Participants in the financing round included exist
Breakthrough ProciseDx diagnostic technology enables quantitative 5-minute tests for Therapeutic Drug Monitoring San Diego, CA- ProciseDx Inc. announces that it is being acquired by Biosynex S.A., a French diagnostics company that specializes in point of care testing. With the support of the Bio
Breakthrough ProciseDx diagnostic technology enables quantitative 5 minute tests. Easy, immediate and accurate results that expedite medical treatment. San Diego, CA- ProciseDx Inc. announces FDA clearance of its ProciseDx instrument and C reactive Protein (CRP) test. Procise CRP gives qua
Founder of Biosynex SA, Dectra Pharm SAS and All Diag
Martin joined NHSc in 2012 with the task of building a healthcare M&A capability for the group. Since then he has kept a relentless passion for growing the company’s portfolio through creative deals, ranging from large M&A transactions to small licensing deals and everything in between.
To stay informed about our company, or to speak with our team, please contact us here or email info@procisediagnostics.com.
Studies and key opinion leaders agree that physicians should consistently monitor these therapeutic treatments to achieve the best results.
Studies and key opinion leaders agree that physicians should consistently monitor these therapeutic treatments to achieve the best results.
